LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 161

Search options

  1. Article: Malignant migrating partial seizures in infancy.

    Coppola, Giangennaro

    Handbook of clinical neurology

    2013  Volume 111, Page(s) 605–609

    Abstract: The syndrome of malignant migrating partial seizures in infancy (MMPSI) was first reported in 1995, and is now included among the childhood epileptic syndromes in the revision proposal of the ILAE Commission on classification and terminology. The main ... ...

    Abstract The syndrome of malignant migrating partial seizures in infancy (MMPSI) was first reported in 1995, and is now included among the childhood epileptic syndromes in the revision proposal of the ILAE Commission on classification and terminology. The main clinical features are seizure onset in the first 6 months of life, occurrence of almost continuous migrating polymorphous focal seizures, associated with multifocal ictal EEG discharges, progressive deterioration of psychomotor development combined with frequent evolution of acquired microcephaly, and lack of a significant familial and etiological context. Eventually, children develop major axial hypotonia, pyramidal and extrapyramidal signs with athetotic movements and strabismus. Neuroradiological, biochemical, and genetic investigations thus far have note contributed to our knowledge about this syndrome. Etiology is still unknown, though it appears reasonable to suspect a genetic etiology for MMPSI; a channelopathy may be responsible for the age-dependent cortical neuronal hyperexcitability. Seizures are markedly drug resistant and outcome is generally severe. However, some patients may respond favourably to bromide, stiripentol associated with clonazepam, and, more recently, to levetiracetam. Vagus nerve stimulation and a ketogenic diet have been tried also but with poor or inconclusive results. Based on age at onset, MMPEI may be placed between early epileptic encephalopthies and infantile spasms.
    MeSH term(s) Electroencephalography ; Epilepsies, Partial/complications ; Epilepsies, Partial/etiology ; Epilepsies, Partial/therapy ; Humans ; Infant ; Infant, Newborn ; Migraine Disorders/complications ; Spasms, Infantile/complications ; Spasms, Infantile/etiology ; Spasms, Infantile/therapy
    Language English
    Publishing date 2013
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 0072-9752
    ISSN 0072-9752
    DOI 10.1016/B978-0-444-52891-9.00062-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Update on rufinamide in childhood epilepsy.

    Coppola, Giangennaro

    Neuropsychiatric disease and treatment

    2011  Volume 7, Page(s) 399–407

    Abstract: Rufinamide is an orally active, structurally novel compound (1-[(2,6-difluorophenil1) methyl1]-1 hydro 1,2,3-triazole-4 carboxamide), which is structurally distinct from other anticonvulsant drugs. It was granted orphan drug status for the adjunctive ... ...

    Abstract Rufinamide is an orally active, structurally novel compound (1-[(2,6-difluorophenil1) methyl1]-1 hydro 1,2,3-triazole-4 carboxamide), which is structurally distinct from other anticonvulsant drugs. It was granted orphan drug status for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in the United States in 2004, and released for use in Europe in 2007. In January 2009, rufinamide was approved by the United States Food and Drug Administration for treatment of LGS in children 4 years of age and older. It is also approved for adjunctive treatment for partial seizures in adults and adolescents. Rufinamide's efficacy mainly against atonic/tonic seizures in patients with LGS seems nowadays indubitable and has been confirmed both in randomized controlled trial and in open label extension studies. More recently, rufinamide was evaluated for the adjunctive treatment of childhood-onset epileptic encephalopathies and epileptic syndromes other than LGS, including epileptic spasms, multifocal epileptic encephalopathy with spasm/tonic seizures, myoclonic-astatic epilepsy, Dravet syndrome and malignant migrating partial seizures in infancy. This review updates the existing literature data on the efficacy and safety/tolerability of rufinamide in childhood-onset epilepsy syndromes.
    Language English
    Publishing date 2011-07-05
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2186503-6
    ISSN 1178-2021 ; 1176-6328
    ISSN (online) 1178-2021
    ISSN 1176-6328
    DOI 10.2147/NDT.S13910
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Correction: Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements.

    Bonanni, Paolo / Gambardella, Antonio / Tinuper, Paolo / Acone, Benedetto / Perucca, Emilio / Coppola, Giangennaro

    BMC neurology

    2022  Volume 22, Issue 1, Page(s) 184

    Language English
    Publishing date 2022-05-17
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2041347-6
    ISSN 1471-2377 ; 1471-2377
    ISSN (online) 1471-2377
    ISSN 1471-2377
    DOI 10.1186/s12883-022-02701-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The Ketogenic Diet in Children with Epilepsy: A Focus on Parental Stress and Family Compliance.

    Operto, Francesca Felicia / Labate, Angelo / Aiello, Salvatore / Perillo, Cristina / de Simone, Valeria / Rinaldi, Rosetta / Coppola, Giangennaro / Pastorino, Grazia Maria Giovanna

    Nutrients

    2023  Volume 15, Issue 4

    Abstract: 1) Background: The aim of our study was to evaluate parental stress after 6 and 12 months of a ketogenic diet, considering demographic and clinical variables (epilepsy type, epilepsy duration, seizure number, antiseizure medications, comorbidities, ... ...

    Abstract (1) Background: The aim of our study was to evaluate parental stress after 6 and 12 months of a ketogenic diet, considering demographic and clinical variables (epilepsy type, epilepsy duration, seizure number, antiseizure medications, comorbidities, efficacy, and adverse events). (2) Methods: We consecutively enrolled 36 children aged between 3 and 10 years who had been diagnosed with various types of drug-resistant epilepsy and who were in therapy with a ketogenic diet for better seizure control. A standardized neuropsychological questionnaire (Parenting Stress Index-PSI) was administered to the parents evaluating parental stress at baseline (T0), after 6 (T1) months, and after 12 months (T2). (3) Results: After 6 and 12 months of dietary treatment, Parental Distress and Total Stress mean scores were statistically significantly increased. Post hoc analysis showed no significant changes in the scores between T0 and T1, although there was a significant increase between T1 and T2. We did not find statistically significant relationships between parental stress and the other variables considered. (4) Conclusions: The ketogenic diet can be challenging for parents and can affect the perception of parental stress, especially in the long term. Parents may feel inadequate in their role; therefore, they should be helped and encouraged through additional supports in order to maximize the adherence to diet therapy.
    MeSH term(s) Humans ; Child ; Child, Preschool ; Diet, Ketogenic/adverse effects ; Treatment Outcome ; Epilepsy ; Seizures ; Parents
    Language English
    Publishing date 2023-02-20
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2518386-2
    ISSN 2072-6643 ; 2072-6643
    ISSN (online) 2072-6643
    ISSN 2072-6643
    DOI 10.3390/nu15041058
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Malignant migrating partial seizures in infancy: an epilepsy syndrome of unknown etiology.

    Coppola, Giangennaro

    Epilepsia

    2009  Volume 50 Suppl 5, Page(s) 49–51

    Abstract: The syndrome of malignant migrating partial seizures in infancy was first reported in 1995, and is now included among the childhood epilepsy syndromes in development in the proposal of the revision of the International League Against Epilepsy (ILAE) ... ...

    Abstract The syndrome of malignant migrating partial seizures in infancy was first reported in 1995, and is now included among the childhood epilepsy syndromes in development in the proposal of the revision of the International League Against Epilepsy (ILAE) classification of the epilepsies and epilepsy syndromes. The main clinical features are seizure onset in the first 6 months of life, occurrence of almost continuous migrating polymorphous focal seizures, combined with multifocal ictal electroencephalography (EEG) discharges, and progressive deterioration of psychomotor development. Etiology is so far unknown. Seizures are markedly drug resistant and outcome is generally severe. Based on age at onset, migrating partial seizures in infancy (MMPEI) may be placed between early epileptic encephalopathies (early myoclonic encephalopathy [EME] and early infantile epileptic encephalopathy [EIEE]) and infantile spasms.
    MeSH term(s) Brain/diagnostic imaging ; Brain/pathology ; Brain/physiopathology ; Disease Progression ; Electroencephalography ; Epilepsies, Partial/diagnosis ; Epilepsies, Partial/etiology ; Epilepsies, Partial/physiopathology ; Humans ; Infant ; Magnetic Resonance Imaging ; Tomography, X-Ray Computed
    Language English
    Publishing date 2009-05
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 216382-2
    ISSN 1528-1167 ; 0013-9580
    ISSN (online) 1528-1167
    ISSN 0013-9580
    DOI 10.1111/j.1528-1167.2009.02121.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements.

    Bonanni, Paolo / Gambardella, Antonio / Tinuper, Paolo / Acone, Benedetto / Perucca, Emilio / Coppola, Giangennaro

    BMC neurology

    2021  Volume 21, Issue 1, Page(s) 410

    Abstract: Background: When use of a single antiseizure medication (ASM) fails to induce seizure remission, add-on therapy is justified. Perampanel (PER) is approved in Europe as adjunctive therapy for focal, focal to bilateral tonic-clonic seizures and ... ...

    Abstract Background: When use of a single antiseizure medication (ASM) fails to induce seizure remission, add-on therapy is justified. Perampanel (PER) is approved in Europe as adjunctive therapy for focal, focal to bilateral tonic-clonic seizures and generalized tonic-clonic seizures. Aim of the study was to establish whether PER is suitable for first add-on use.
    Methods: A Delphi methodology was adopted to assess consensus on a list of 39 statements produced by an Expert Board of 5 epileptologists. Using an iterative process, statements were finalized by a Delphi Panel of 84 Italian pediatric and adult neurologists. Each statement was rated anonymously to determine level of agreement on a 9-point Likert scale. Consensus was established as agreement by at least 80% of the panelists. The relevance of each statement was also assessed on a 3-point scale.
    Results: Consensus was achieved for 37 statements. Characteristics of PER considered to justify its use as first add-on include evidence of a positive impact on quality of life based on long term retention data, efficacy, tolerability, and ease of use; no worsening of cognitive functions and sleep quality; a low potential for drug interactions; a unique mechanism of action. Potential unfavorable factors are the need for a relatively slow dose titration; the potential occurrence of behavioral adverse effects; lack of information on safety when used in pregnancy; limited access to plasma PER levels.
    Conclusion: Perampanel has many features which justify its use as a first add-on. Choice of an ASM as first add-on should be tailored to individual characteristics.
    MeSH term(s) Adult ; Anticonvulsants/therapeutic use ; Child ; Consensus ; Humans ; Italy ; Nitriles ; Pyridones/therapeutic use ; Quality of Life ; Treatment Outcome
    Chemical Substances Anticonvulsants ; Nitriles ; Pyridones ; perampanel (H821664NPK)
    Language English
    Publishing date 2021-10-26
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041347-6
    ISSN 1471-2377 ; 1471-2377
    ISSN (online) 1471-2377
    ISSN 1471-2377
    DOI 10.1186/s12883-021-02450-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Selection of antiseizure medications for first add-on use: A consensus paper.

    Gambardella, Antonio / Tinuper, Paolo / Acone, Benedetto / Bonanni, Paolo / Coppola, Giangennaro / Perucca, Emilio

    Epilepsy & behavior : E&B

    2021  Volume 122, Page(s) 108087

    Abstract: Introduction: When monotherapy used alone or sequentially fails to achieve seizure control, a trial of combination therapy may be considered.: Objective: To define optimal criteria to guide choice of an antiseizure medication (ASM) for use as first ... ...

    Abstract Introduction: When monotherapy used alone or sequentially fails to achieve seizure control, a trial of combination therapy may be considered.
    Objective: To define optimal criteria to guide choice of an antiseizure medication (ASM) for use as first add-on.
    Methods: A standardized Delphi procedure was applied to produce a list of consensus statements. First, an Expert Board consisting of 5 epileptologists agreed on a set of 46 statements relevant to the objective. The statements were then finalized through an iterative process by a Delphi Panel of 84 Italian pediatric and adult neurologists with expertise in the management of epilepsy. Panel members provided anonymous ratings of their level of agreement with each statement on a 9-point Likert scale.
    Results: Consensus, defined as agreement by at least 80% of Panel members, was reached for 36 statements. Medication-related factors considered to be important for drug selection included efficacy, tolerability and safety, interaction potential, mechanism of action, and ease of use. The need to optimize adherence and to tailor drug selection to individual characteristics was emphasized.
    Conclusions: Choice of an ASM for first add-on requires consideration of many factors, many of which also apply to choose initial treatment. Factors more specifically relevant to add-on use include drug interaction potential and the preference for an ASM with a different mechanism of action.
    MeSH term(s) Adult ; Child ; Consensus ; Epilepsy/drug therapy ; Humans ; Italy
    Language English
    Publishing date 2021-06-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2010587-3
    ISSN 1525-5069 ; 1525-5050
    ISSN (online) 1525-5069
    ISSN 1525-5050
    DOI 10.1016/j.yebeh.2021.108087
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Epilepsy and Cognitive Impairment in Childhood and Adolescence: A Mini-Review.

    Operto, Francesca Felicia / Pastorino, Grazia Maria Giovanna / Viggiano, Andrea / Dell'Isola, Giovanni Battista / Dini, Gianluca / Verrotti, Alberto / Coppola, Giangennaro

    Current neuropharmacology

    2022  Volume 21, Issue 8, Page(s) 1646–1665

    Abstract: Managing epilepsy in people with an intellectual disability remains a therapeutic challenge and must take into account additional issues such as diagnostic difficulties and frequent drug resistance. Advances in genomic technologies improved our ... ...

    Abstract Managing epilepsy in people with an intellectual disability remains a therapeutic challenge and must take into account additional issues such as diagnostic difficulties and frequent drug resistance. Advances in genomic technologies improved our understanding of epilepsy and raised the possibility to develop patients-tailored treatments acting on the key molecular mechanisms involved in the development of the disease. In addition to conventional antiseizure medications (ASMs), ketogenic diet, hormone therapy and epilepsy surgery play an important role, especially in cases of drugresistance. This review aims to provide a comprehensive overview of the mainfactors influencing cognition in children and adolescents with epilepsy and the main therapeutic options available for the epilepsies associated with intellectual disability.
    MeSH term(s) Child ; Humans ; Adolescent ; Intellectual Disability ; Epilepsy/drug therapy ; Cognitive Dysfunction ; Diet, Ketogenic ; Cognition
    Language English
    Publishing date 2022-06-15
    Publishing country United Arab Emirates
    Document type Review ; Journal Article
    ZDB-ID 2192352-8
    ISSN 1875-6190 ; 1570-159X
    ISSN (online) 1875-6190
    ISSN 1570-159X
    DOI 10.2174/1570159X20666220706102708
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Monitoring And Managing Depression In Adolescents With Epilepsy: Current Perspectives.

    Coppola, Giangennaro / Operto, Francesca Felicia / Matricardi, Sara / Verrotti, Alberto

    Neuropsychiatric disease and treatment

    2019  Volume 15, Page(s) 2773–2780

    Abstract: Epilepsy is associated with a significantly increased risk of developing depressive disorder during adolescence. On the other hand, depression is highly detected in adolescents with epilepsy. These findings highlight the importance of early ... ...

    Abstract Epilepsy is associated with a significantly increased risk of developing depressive disorder during adolescence. On the other hand, depression is highly detected in adolescents with epilepsy. These findings highlight the importance of early identification and proper management of comorbid depression in adolescent age. The prevalence of depressive disorders in adolescents with epilepsy ranges between 8 and 35% and is higher than the general population of the same age. The relationship between epilepsy and depression is complex and potentially bidirectional, thereby suggesting a common underlying pathophysiology. Furthermore, failure to detect and treat depressive disorder mostly in adolescence could lead to several negative implications such as an increased risk of suicidal ideation or behavior and poor quality of life. A number of methods are available to detect depressive disorder, such as psychiatric or psychological assessments, structured or semi-structured interviews, and self-report screening tools. Thus, physicians should be able to regularly screen depressive symptoms in youths with epilepsy. Recently, the NDDI-E-.Y inventory has been developed from the adult NDDI-E, and has been validated in many countries. NDDI-E-Y has showed reliable validity, being a brief screening tool (12 items) that can be easily included in routine epilepsy care. The first step to be considered for the management of depressive disorder in adolescents with epilepsy is to consider potential reversible causes of anxiety and depression (i.e., a new AEDs; seizure control). Secondly, great attention has to be given to the education of the child/adolescent and his/her family, trying to improve knowledge about epilepsy as well as to decrease parental stress and improving the child's sense of competence. Pharmacological treatment should also be considered in adolescents diagnosed with depression.
    Language English
    Publishing date 2019-09-24
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2186503-6
    ISSN 1178-2021 ; 1176-6328
    ISSN (online) 1178-2021
    ISSN 1176-6328
    DOI 10.2147/NDT.S192714
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Familial Hemiplegic Migraine with an ATP1A4 Mutation: Clinical Spectrum and Carbamazepine Efficacy.

    Coppola, Giangennaro / Pastorino, Grazia Maria Giovanna / Vetri, Luigi / D'Onofrio, Floriana / Operto, Francesca Felicia

    Brain sciences

    2020  Volume 10, Issue 6

    Abstract: An Italian family with familial hemiplegic migraine (FHM) with the absence of mutations in the known genes associated with this disorder, ... ...

    Abstract An Italian family with familial hemiplegic migraine (FHM) with the absence of mutations in the known genes associated with this disorder, namely
    Language English
    Publishing date 2020-06-15
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2651993-8
    ISSN 2076-3425
    ISSN 2076-3425
    DOI 10.3390/brainsci10060372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top